Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Achieve Life Sciences  / Equity Bottom-Up

<ul><li>Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.</li><li>Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.</li><li>Results exceeded expectations on safety & efficacy parameters.</li></ul>

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world.Topline results from ORCA-2 were reported in April 2022 and for ORCA-3 in May 2023.Results exceeded expectations on safety & efficacy parameters.

United States

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies for treating a variety of diseases, such as cancer, vascular disease, inflammatory skin disease, and diabetes.

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company. The Company develops novel therapeutics for the treatment of various forms of cancer. Puma focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

Clovis Oncology Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.  Clovis target its development programs for the treatment of specific subsets of cancer populations.

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

Atossa Therapeutics, Inc. operates as a biopharmaceutical company. The Company discovers proprietary therapeutics and delivery methods for breast cancer and other related conditions. Atossa Therapeutics serves customers worldwide.

PDS Biotechnology Corp operates as a clinical-stage biotechnology company. The Company develops immuno-oncology therapies to treat various early and late stage cancers including head and neck, prostate, breast, cervical, and anal cancers. PDS Biotechnology serves patients worldwide.

Corvus Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the development of novel and first-in-class agents that target the immune system to treat patients with cancer. Corvus Pharmaceuticals offers its services in the United States.

Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company. The Company specializes in novel therapeutics to treat chronic and high-prevalence retinal diseases. Kodiak Sciences serves customers in the Unites States.

Seres Therapeutics, Inc. operates as a microbiome therapeutics platform company. The Company focuses on developing biological drugs, which are designed to restore health by repairing the function of a dysbiotic microbiome. Seres Therapeutics also conducts research on metabolic diseases.

Lineage Cell Therapeutics, Inc. operates as a biotechnology company. The Company offers cell-based therapies and gene marker-based molecular diagnostics for diseases and degenerative conditions. Lineage Cell Therapeutics serves patients in the United States.

CellSeed Inc. develops Cell-sheet regenerative medicine. The company cultures cells and builds cell-sheets to regenerate lost or functionally imparied tissues and organs. CellSeed Inc. also supports regenerative medicine industry by providing leading technology and solutions.

ISU ABXIS Co., Ltd. develops therapeutic antibodies for such as antithrombus, anti-inflammatory, anti-cancer, and rare diseases.  The Company also provides medical service such as anti-cancer drug sensitivity examination and gene examination.

Essex Bio-Technology Limited manufactures and sells biopharmaceutical products for the treatment and healing of surface wounds and organ wounds.

iNtRON Biotechnology, Inc. is a bio-venture developing bio-active agents targeting infectious organisms and driving its commercial use.

NIBEC Co Ltd. manufactures, researches, and develops medical and dental products.  The Company's products include a Bulyonghwa treatment of residual protein and teeth whitening products.

Medigen Biotechnology Corp. researches and develops anti-cancer biopharmaceuticals.

Actinogen Medical Limited operates as a biotechnology company. The Company focuses on the treatment of alzheimer's disease and mild cognitive impairment. Actinogen Medical develops a novel drug to treat the condition and other age-related neurodegenerative diseases.

CrystalGenomics Incorporation develops pharmaceutical and agricultural products by structure-based drug discovery technology.  The Company also provides structural proteomic analysis services for helping drug discovery process.

Cellectis SA is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells.

Innate Pharma S.A. is a biopharmaceutical company.  The Company develops first in class drugs that focus on cancer immunotherapy through the manipulation of the innate immune system.

Achieve Life Sciences, Inc. operates as a pharmaceutical company. The Company develops and commercializes cytisine treatment to help people battling nicotine addiction. Achieve Life Sciences serves customers in North America.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Achieve Life Sciences (ACHV US)

ACHV: First Quarter Results

Achieve Life Sciences is developing cytisinicline for use as a smoking cessation treatment in the United States and rest of world. Topline results...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)